Veramyst

(Fluticasone furoate)

ApprovedSmall molecule

Fluticasone furoate is an inhaled steroid used to prevent asthma attacks and reduce inflammation in the airways. It's also used as a nasal spray to relieve allergy symptoms like congestion and sneezing.[2] Veramyst is currently approved and in use across 18 indications[4].[1]

Veramyst is one of 394 small molecule programs targeting Emphysema. It is currently in Approved.

Indications

134

Total Trials

Active Trials

393

Competitors

Pipeline

Status by Indication[4][1]

Indication

EmphysemaUnknown

Cardiovascular DiseaseActive, not recruiting

AllergyActive, not recruiting

Airway ObstructionUnknown

RhinitisActive, not recruiting

Rhinitis, Allergic, PerennialUnknown

Obstructive Sleep ApneaActive, not recruiting

Chronic Obstructive Pulmonary DiseaseUnknown

BronchitisUnknown

Nasal CongestionUnknown

EmphysemaPreclinical

Unknown

Cardiovascular DiseasePhase 3

Active, not recruiting

AllergyApproved

Active, not recruiting

Airway ObstructionPreclinical

Unknown

RhinitisPhase 3

Active, not recruiting

Rhinitis, Allergic, PerennialPreclinical

Unknown

Obstructive Sleep ApneaApproved

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Unknown

BronchitisPreclinical

Unknown

Nasal CongestionPreclinical

Unknown

Showing 10 of 18 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Veramyst

Spikevax

21 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Biaxin

AbbVie

Preclinical

2 5

Stivarga

Bayer

Preclinical

1 6

Aimovig

Amgen

Preclinical

1 7

Aldactone

Pfizer

Preclinical

1 8

Nexavar

Bayer

Preclinical

1 9

Singulair

AstraZeneca

Preclinical

1 10

Calciferol

Alnylam Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma46 trials

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Completed· GSK logo

GSK·Phase 2·NCT01128569·52 enrolled

Study Of Asthma In Patients Of African Descent

Completed· GSK logo

GSK·Phase 4·NCT00102765·479 enrolled

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Completed· GSK logo

GSK·Phase 4·NCT00118716·248 enrolled

Show 43 more trials

An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma

Completed· GSK logo

GSK·Phase 3·NCT01706198·4,233 enrolled

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Completed· GSK logo

GSK·Phase 3·NCT01134042·587 enrolled

Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics

Withdrawn·AActavis Inc.·Phase 3·NCT02496715

Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics

Completed· GSK logo

GSK·Phase 1·NCT00364442·12 enrolled

Asthma Exacerbation Study

Completed· GSK logo

GSK·Phase 3·NCT01086384·2,020 enrolled

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Completed· GSK logo

GSK·Phase 3·NCT01159912·350 enrolled

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

Completed· GSK logo

GSK·Phase 4·NCT02889809·477 enrolled

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

Completed· GSK logo

GSK·Phase 2·NCT01332292·27 enrolled

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Completed· GSK logo

GSK·Phase 4·NCT00452348·628 enrolled

Treatment Of Symptomatic Asthma In Children

Completed· GSK logo

GSK·Phase 4·NCT00197106·176 enrolled

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Completed· GSK logo

GSK·Phase 3·NCT00441441·351 enrolled

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

Completed· Teva logo

Teva·Phase 4·NCT04677959·427 enrolled

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Completed· GSK logo

GSK·Phase 2·NCT02991859·56 enrolled

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Completed· GSK logo

GSK··NCT01347060·17,448 enrolled

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Completed· GSK logo

GSK·Phase 4·NCT00118690·227 enrolled

Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma

Completed· GSK logo

GSK·Phase 3·NCT01687296·261 enrolled

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Completed· Teva logo

Teva·Phase 1·NCT02680561·20 enrolled

Spacer Comparison In Adult Asthmatics

Completed· GSK logo

GSK·Phase 2·NCT00369993·20 enrolled

A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler

Withdrawn· GSK logo

GSK·Phase 1·NCT02218762

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Completed· Novartis logo

Novartis·Phase 2·NCT00557440·37 enrolled

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Completed· GSK logo

GSK·Phase 3·NCT02301975·1,526 enrolled

A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

Withdrawn· GSK logo

GSK·Phase 3·NCT01435902

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

Completed· GSK logo

GSK·Phase 3·NCT02502734·60 enrolled

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Completed· GSK logo

GSK·Phase 3·NCT02446418·423 enrolled

A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

Completed· GSK logo

GSK·Phase 3·NCT02094937·430 enrolled

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Completed· GSK logo

GSK·Phase 3·NCT01436071·248 enrolled

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

Completed· GSK logo

GSK·Phase 3·NCT01686633·1,040 enrolled

A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.

Completed· GSK logo

GSK·Phase 2·NCT02712047·28 enrolled

To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma

Completed· GSK logo

GSK·Phase 2·NCT01808339·28 enrolled

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Completed· GSK logo

GSK·Phase 3·NCT01436110·351 enrolled

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Completed· GSK logo

GSK·Phase 2·NCT03207243·165 enrolled

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

Completed· GSK logo

GSK·Phase 4·NCT00353873·506 enrolled

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

Completed· GSK logo

GSK·Phase 4·NCT00102882·547 enrolled

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

Completed· GSK logo

GSK·Phase 4·NCT00452699·621 enrolled

Study Of RV-39 In Patients Who Also Have Asthma

Terminated· GSK logo

GSK·Phase 4·NCT00503009·16 enrolled

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma

Completed· GSK logo

GSK·Phase 3·NCT01244984·243 enrolled

Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma

Completed· GSK logo

GSK·Phase 3·NCT01687283·316 enrolled

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Completed· GSK logo

GSK·Phase 4·NCT02730351·75 enrolled

Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Completed· GSK logo

GSK·Phase 3·NCT01165138·612 enrolled

The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma

Withdrawn· GSK logo

GSK·Phase 4·NCT03363191

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Completed· GSK logo

GSK·Phase 2·NCT03012061·425 enrolled

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Completed· GSK logo

GSK·Phase 2·NCT01128595·27 enrolled

Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

Completed· GSK logo

GSK·Phase 3·NCT01431950·238 enrolled

Chronic Obstructive Pulmonary Disease26 trials

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Completed· GSK logo

GSK·Phase 3·NCT01072149·54 enrolled

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Completed· GSK logo

GSK·Phase 4·NCT00784550·342 enrolled

Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.

Completed· GSK logo

GSK·Phase 4·NCT00355342·186 enrolled

Show 23 more trials

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

Completed· GSK logo

GSK·Phase 4·NCT01957150·283 enrolled

SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease

Completed· GSK logo

GSK·Phase 4·NCT00361959·1,270 enrolled

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK·Phase 3·NCT01323621·512 enrolled

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Completed· GSK logo

GSK·Phase 3·NCT00269126·150 enrolled

GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Completed· GSK logo

GSK·Phase 3·NCT00269087·122 enrolled

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Terminated· GSK logo

GSK·Phase 4·NCT00346749·180 enrolled

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Completed· GSK logo

GSK·Phase 4·NCT00115492·797 enrolled

Chronic Obstructive Pulmonary Disease Endpoints Study

Completed· GSK logo

GSK·Phase 4·NCT00358358·163 enrolled

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Completed· GSK logo

GSK·Phase 4·NCT00633217·247 enrolled

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Completed· GSK logo

GSK·Phase 3·NCT01313676·16,568 enrolled

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK··NCT01381471·11,060 enrolled

Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies

Completed· GSK logo

GSK··NCT01332461·5,677 enrolled

Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

Completed· GSK logo

GSK·Phase 3·NCT00549146·290 enrolled

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Completed· GSK logo

GSK··NCT01387178·22,223 enrolled

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Withdrawn· GSK logo

GSK·Phase 3·NCT02731846

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Completed· GSK logo

GSK·Phase 4·NCT00984659·366 enrolled

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK·Phase 3·NCT01817764·707 enrolled

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK·Phase 3·NCT02164513·10,355 enrolled

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK·Phase 3·NCT02105974·1,621 enrolled

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Completed· GSK logo

GSK·Phase 4·NCT00144911·740 enrolled

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

Completed· GSK logo

GSK·Phase 3·NCT01323634·519 enrolled

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed· GSK logo

GSK·Phase 3·NCT01822899·717 enrolled

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study

Withdrawn· GSK logo

GSK·Phase 4·NCT03949842

Allergic Rhinitis10 trials

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Completed· GSK logo

GSK·Phase 4·NCT00296491·725 enrolled

Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

Completed· GSK logo

GSK·Phase 3·NCT01630135·261 enrolled

Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation

Completed·NNanhua University·N/A·NCT03673384·50 enrolled

Show 7 more trials

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Completed· GSK logo

GSK·Phase 3·NCT01231464·365 enrolled

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Completed· GSK logo

GSK·Phase 4·NCT00609674·315 enrolled

Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting

Terminated· GSK logo

GSK··NCT01337323·3 enrolled

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Completed· GSK logo

GSK·Phase 4·NCT00682643·550 enrolled

Study Of Patients With Allergic Rhinitis And Asthma

Completed· GSK logo

GSK·Phase 4·NCT00296530·600 enrolled

Intranasal Steroids and Oxymetazoline in Allergic Rhinitis

Completed·UUniversity of Chicago·Phase 4·NCT00584987·64 enrolled

Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

Completed· GSK logo

GSK·Phase 3·NCT01622231·61 enrolled

Efficacy and Safety4 trials

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Completed· GSK logo

GSK·Phase 2·NCT01147744·700 enrolled

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

Completed· GSK logo

GSK·Phase 3·NCT01147848·810 enrolled

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Completed· GSK logo

GSK·Phase 3·NCT01772134·617 enrolled

Show 1 more trial

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Completed· GSK logo

GSK·Phase 3·NCT01772147·608 enrolled

Acute Lymphoblastic Leukemia3 trials

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

Completed·UUniversity of Chicago·Phase 4·NCT00791973·15 enrolled

Effect of Fluticasone Furoate on Methacholine Challenge

Completed·UUniversity of Saskatchewan·Phase 4·NCT03898466·14 enrolled

Effect of Vilanterol on Methacholine Challenge Results

Completed·UUniversity of Saskatchewan·Phase 4·NCT03315000·17 enrolled

27 more indications

COPD3 trials

A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

Completed· GSK logo

GSK·Phase 3·NCT01376245·646 enrolled

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

Completed· GSK logo

GSK·Phase 3·NCT01192191·187 enrolled

Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

Completed· GSK logo

GSK·Phase 4·NCT01762800·407 enrolled

Salmeterol3 trials

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

Completed·WWest-Ward Pharmaceutical·N/A·NCT03535870·1,556 enrolled

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Completed· Teva logo

Teva·Phase 3·NCT02980133·841 enrolled

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Completed· GSK logo

GSK··NCT01332357·6,139 enrolled

Tics2 trials

Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination

Completed· GSK logo

GSK·Phase 1·NCT02064504·48 enrolled

An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT01449799·24 enrolled

Oral2 trials

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Completed· GSK logo

GSK·Phase 4·NCT00502775·680 enrolled

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Completed· GSK logo

GSK·Phase 4·NCT00435461·1,000 enrolled

Intravenous2 trials

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects

Completed· GSK logo

GSK·Phase 1·NCT01000597·80 enrolled

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01299558·16 enrolled

MPA2 trials

An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo

Withdrawn·OORA, Inc.·Phase 4·NCT01076439

Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination

Completed· GSK logo

GSK·Phase 1·NCT01485445·30 enrolled

Allergy2 trials

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Completed·RRush University Medical Center·Phase 4·NCT00891436·20 enrolled

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

Completed·UUniversity of Chicago·Phase 4·NCT01007253·21 enrolled

Seasonal Allergic Rhinitis2 trials

Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis

Completed·WWestern Sky Medical Research·Phase 4·NCT00997620·40 enrolled

Study In Adults And Adolescents With Seasonal Allergic Rhinitis

Completed· GSK logo

GSK·Phase 3·NCT00115622·304 enrolled

Treatment2 trials

A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects

Completed· GSK logo

GSK·Phase 4·NCT01751113·53 enrolled

Medical vs Surgical Treatment in OSA Among Children

Unknown status·—·Phase 4·NCT05651750·90 enrolled

Inflammation1 trial

INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol

Completed·UUniversity of Dundee·Phase 4·NCT03152149·80 enrolled

Corticosteroids1 trial

Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

Completed· GSK logo

GSK··NCT01332344·5,180 enrolled

TED1 trial

Corrected QT (QTc) Study With Flucticasone Furoate and GW642444

Completed· GSK logo

GSK·Phase 1·NCT01209026·85 enrolled

Cardiovascular Disease1 trial

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

Completed· GSK logo

GSK·Phase 3·NCT01627327·623 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.

Unknown status·—·Phase 1/2·NCT05143502·60 enrolled

Rhinitis1 trial

A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis

Completed· GSK logo

GSK·Phase 2·NCT00730756·102 enrolled

Growth1 trial

Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.

Completed· GSK logo

GSK·Phase 4·NCT00570492·474 enrolled

Patient Preference1 trial

Fluticasone Nasal Spray Patient Preference Study

Completed· GSK logo

GSK·Phase 3·NCT00398476·127 enrolled

Arterial Stiffness1 trial

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Completed· GSK logo

GSK·Phase 3·NCT01336608·446 enrolled

Airway Disease1 trial

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

Completed·TThammasat University·Phase 4·NCT06905483·22 enrolled

LAM1 trial

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

Completed· GSK logo

GSK·Phase 3·NCT01086410·185 enrolled

Drug1 trial

Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects

Completed· GSK logo

GSK·Phase 1·NCT00625196·16 enrolled

Cognition1 trial

Rhinitis, Cognition and Driving Performance

Completed·MMaastricht University Medical Center·N/A·NCT01318681·22 enrolled

Steroid1 trial

Intranasal Steroids and the Nasal Ocular Response

Completed·UUniversity of Chicago·Phase 4·NCT00473915·20 enrolled

Outcome1 trial

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Completed· GSK logo

GSK··NCT01199757·540 enrolled

Obstructive Sleep Apnea1 trial

Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome

Completed·UUniversity of Chicago·Phase 4·NCT00603044·24 enrolled

Polyp1 trial

Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease

Terminated·JJohns Hopkins University·Phase 4·NCT01013701·7 enrolled

Unspecified8 trials

RELOVAIR® Lung Deflation Study

Completed· GSK logo

GSK·Phase 3·NCT01691885·45 enrolled

A Dose-ranging Study of Fluticasone Furoate (FF)

Completed· GSK logo

GSK·Phase 2·NCT01563029·597 enrolled

ROTAHALER Device Optimization Study

Completed· GSK logo

GSK·Phase 1·NCT01890863·36 enrolled

Show 5 more trials

Relovair PD PK in Chinese Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01711463·16 enrolled

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

Completed· GSK logo

GSK·Phase 3·NCT01018186·503 enrolled

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Completed· GSK logo

GSK·Phase 2·NCT01453023·26 enrolled

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

Completed· GSK logo

GSK·Phase 1·NCT01213849·24 enrolled

Regulatory AVAMYS Nasal Spray PMS

Completed· GSK logo

GSK··NCT01001130·3,244 enrolled

Sources

References

[1]
ClinicalTrials.gov — 134 trial records for Fluticasone furoate. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Veramyst drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Fluticasone furoate compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Fluticasone furoate. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: GSK

Veramyst

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Asthma46 trials

Chronic Obstructive Pulmonary Disease26 trials

Allergic Rhinitis10 trials

Efficacy and Safety4 trials

Acute Lymphoblastic Leukemia3 trials

COPD3 trials

Salmeterol3 trials

Tics2 trials

Oral2 trials

Intravenous2 trials

MPA2 trials

Allergy2 trials

Seasonal Allergic Rhinitis2 trials

Treatment2 trials

Inflammation1 trial

Corticosteroids1 trial

TED1 trial

Cardiovascular Disease1 trial

Chronic Rhinosinusitis With Nasal Polyps1 trial

Rhinitis1 trial

Growth1 trial

Patient Preference1 trial

Arterial Stiffness1 trial

Airway Disease1 trial

LAM1 trial

Drug1 trial

Cognition1 trial

Steroid1 trial

Outcome1 trial

Obstructive Sleep Apnea1 trial

Polyp1 trial

Unspecified8 trials

References

Drug Info

Quick Facts

Related News